Posted by Michael Wonder on 24 Feb 2022
AbbVie announces provincial reimbursement for Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia in Alberta, Saskatchewan, British Columbia and Manitoba
24 February 2022 - AbbVie announced today that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse Venclexta (venetoclax) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
The regimen combines six 28 day cycles of obinutuzumab with 12 cycles of Venclexta.
For full funding criteria, consult the list of medications in effect in each province. The combination treatment is also listed on the Drug Benefit List in the Non-Insured Health Benefits Program and has been on Québec’s Listes des médicaments - Établissements since last November.
